CD44 and neoplasm: This differential effect did not appear to be due to enhanced in vivo inhibition of phospho-targets, reduced cell surface CD44 expression (known to correlate with MOC cell aggressiveness [20]), reduced tumor cell proliferation, reduced tumor vascularization or expression of angiogenic cytokines or enhanced tumor cell apoptosis, all of which were similarly or more significantly altered by MEK inhibition.